GSA Capital Partners’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-12,885
| Closed | -$51K | – | 1712 |
|
|
2025
Q3 | $51K | Sell |
12,885
-22,683
| -64% | -$155K | ﹤0.01% | 1571 |
|
|
2025
Q2 | $427K | Buy |
35,568
+22,129
| +165% | +$275K | 0.03% | 1028 |
|
|
2025
Q1 | $185K | Buy |
+13,439
| New | +$193K | 0.02% | 1409 |
|
|
2022
Q3 | – | Sell |
-6,540
| Closed | -$144K | – | 1560 |
|
|
2022
Q2 | $144K | Buy |
6,540
+1,322
| +25% | +$32.1K | 0.02% | 1157 |
|
|
2022
Q1 | $179K | Buy |
+5,218
| New | +$156K | 0.02% | 1199 |
|
|
2021
Q1 | – | Sell |
-3,989
| Closed | -$164K | – | 1149 |
|
|
2020
Q4 | $164K | Buy |
3,989
+443
| +12% | +$11.5K | 0.03% | 1033 |
|
|
2020
Q3 | $82K | Sell |
3,546
-60
| -2% | -$1.55K | 0.01% | 1152 |
|
|
2020
Q2 | $102K | Buy |
+3,606
| New | +$106K | 0.06% | 482 |
|
|
2019
Q3 | – | Sell |
-8,468
| Closed | -$123K | – | 1432 |
|
|
2019
Q2 | $123K | Sell |
8,468
-6,990
| -45% | -$125K | 0.01% | 1320 |
|
|
2019
Q1 | $320K | Buy |
15,458
+7,457
| +93% | +$148K | 0.03% | 952 |
|
|
2018
Q4 | $128K | Buy |
8,001
+1,334
| +20% | +$62.6K | 0.01% | 1192 |
|
|
2018
Q3 | $615K | Buy |
6,667
+3,340
| +100% | +$397K | 0.03% | 971 |
|
|
2018
Q2 | $534K | Buy |
+3,327
| New | +$561K | 0.03% | 1125 |
|
|
2018
Q1 | – | Sell |
-840
| Closed | -$88K | – | 1622 |
|
|
2017
Q4 | $88K | Sell |
840
-3,440
| -80% | -$369K | 0.01% | 1486 |
|
|
2017
Q3 | $561K | Buy |
+4,280
| New | +$523K | 0.04% | 894 |
|
Other funds holding CLSD
GSA Capital Partners's CLSD Position: Q4 2025 in Review
GSA Capital Partners sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 12,885 shares — an estimated $51K sold.
GSA Capital Partners first reported a position in CLSD in Q3 2017 and held it in 15 quarters. The position peaked at $615K in Q3 2018. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- GSA Capital Partners reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- GSA Capital Partners sold 12,885 Clearside Biomedical shares in Q4 2025, an estimated $51K.
- GSA Capital Partners first reported a position in Clearside Biomedical in Q3 2017 and held it in 15 quarters.
- GSA Capital Partners's Clearside Biomedical position peaked at $615K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.